[HTML][HTML] Molecular biology of lung cancer
WA Cooper, DCL Lam, SA O'Toole… - Journal of thoracic …, 2013 - ncbi.nlm.nih.gov
Lung cancers are characterised by abundant genetic diversity with relatively few recurrent
mutations occurring at high frequency. However, the genetic alterations often affect a …
mutations occurring at high frequency. However, the genetic alterations often affect a …
New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment
Lung cancer is the foremost reason of death from cancers with broad genetic and epigenetic
diversity. Various strategies are clinically available for diagnosis and treatment of lung …
diversity. Various strategies are clinically available for diagnosis and treatment of lung …
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Objectives Immune checkpoint blockade using inhibitors of programmed death-1 have
shown promise in early phase clinical trials in NSCLC and programmed death-ligand 1 (PD …
shown promise in early phase clinical trials in NSCLC and programmed death-ligand 1 (PD …
[HTML][HTML] Comparison of four PD-L1 immunohistochemical assays in lung cancer
Introduction Four different programmed death ligand 1 immunohistochemical assays are
approved or in development as companion or complementary diagnostics to different …
approved or in development as companion or complementary diagnostics to different …
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform …
Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity)
in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and …
in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and …
Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities
MA Ortega, F Navarro, L Pekarek… - International …, 2022 - spandidos-publications.com
Lung cancer represents one of the most common neoplasms and the main cause of cancer‑
associated death worldwide. Its relationship with different risk factors such as tobacco, which …
associated death worldwide. Its relationship with different risk factors such as tobacco, which …
A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma
Pathogenic ALK translocations have been reported in papillary thyroid carcinoma (PTC). We
developed and validated a screening algorithm based on immunohistochemistry (IHC) …
developed and validated a screening algorithm based on immunohistochemistry (IHC) …
Immunohistochemistry of pulmonary biomarkers: a perspective from members of the pulmonary pathology society
E Thunnissen, TC Allen, J Adam… - … of pathology & …, 2018 - meridian.allenpress.com
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers
is a well-established and powerful technique. Immunohistochemisty is readily available in …
is a well-established and powerful technique. Immunohistochemisty is readily available in …
Current status of targeted therapy for anaplastic lymphoma kinase–rearranged non–small cell lung cancer
B Solomon, KD Wilner, AT Shaw - CLINICAL PHARmACOLOgy …, 2014 - Wiley Online Library
The identification of chromosomal rearrangements involving the anaplastic lymphoma
kinase (ALK) gene in~ 3–5% of non–small cell lung cancer (NSCLC) tissues and the …
kinase (ALK) gene in~ 3–5% of non–small cell lung cancer (NSCLC) tissues and the …
[HTML][HTML] Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond
C Khoo, TM Rogers, A Fellowes, A Bell… - … lung cancer research, 2015 - ncbi.nlm.nih.gov
Somatic mutational profiling in cancer has revolutionized the practice of clinical oncology.
The discovery of driver mutations in non-small cell lung cancer (NSCLC) is an example of …
The discovery of driver mutations in non-small cell lung cancer (NSCLC) is an example of …